How does Brivaracetam 75mg tablets work?

The precise mechanism of brivaracetam's anti-epileptogenic activity is unknown. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Brivaracetam 75mg tablets?

Brivaracetam 75mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Brivaracetam 75mg tablets?

Brivaracetam 75mg tablets is the generic name. It is available under brand names including: Briviact 75mg tablets, Briviact 75mg tablets, Briviact 75mg tablets, Briviact 75mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Brivaracetam 75mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

75mg

Oral

Antiepileptic

Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures.

Active ingredients:

Brivaracetam

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 04.08.01

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N03AX23

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Primary care groupBrowse groups

NHS medication clusters used to compare prescribing patterns across GP practices

Antiepileptic

Check interactions for Brivaracetam

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Brivaracetam

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Brivaracetam

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Brivaracetam

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

4 branded products available

4 productsShow details

4 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Brivaracetam on the MHRA register

Briviact 75mg tablets

UCB Pharma Ltd

Briviact 75mg tablets

Ethigen Ltd

Briviact 75mg tablets

Pharmaram Ltd

Briviact 75mg tablets

CST Pharma Ltd

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Price & daily doseShow details

£129.64indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

100 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Zonisamide 200mg capsules

Capsule

200mg

Same therapeutic group

Sultiame 20mg/ml oral suspension

Oral suspension

20mg

Same therapeutic group

Zonisamide 20mg/ml oral suspension sugar free

Oral suspension

20mg

Same therapeutic group

Topiramate 20mg/ml oral solution sugar free

Oral solution

20mg

Same therapeutic group

Lamotrigine 10mg/ml oral suspension sugar free

Oral suspension

10mg

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Brivaracetam

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(2)

Cenobamate for treating focal onset seizures in epilepsy (TA753)

TA753

Technology appraisal

Updated Jul 2025

Epilepsies in children, young people and adults (NG217)

NG217

NICE guideline

Updated Jan 2025

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Brivaracetam

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

31534511000001106

dm+d ID

31534511000001106

VTM (Virtual Therapeutic Moiety)

774912006

VMP (Virtual Medicinal Product)

31534511000001106

BNF code

04080100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N03AX23

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

1 found

Half-life

7-8h

Mechanism

The precise mechanism of brivaracetam's anti-epileptogenic activity is unknown.

Food interactions

2 warnings

Human targets

2 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

100%

Nearly 100% oral bioavailability .
[A19180]

Half-life

7-8h

7-8h .
[A19180]

Protein binding

20%

<20% bound to plasma proteins [FDA Label].

Volume of distribution

0.5L/kg

0.5L/kg [FDA Label].

Metabolism

Primarily metabolized by hydrolysis of the acetamide moeity to form a carboxylic acid metabolite .
[A19188]…

Elimination

95%

\>95% excreted in urine with <10% of the parent compound unchanged. <1% excreted in feces [FDA Label].

Clearance

0.7-1.07 mL/min

CL/F of 0.7-1.07 mL/min kg .
[A19187]
Clearance is primarily metabolic with less than 10% of the parent drug excreted unchanged.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760].

Properties:

solid

Avg. mass: 212.29 Da

View FDA drug label

DrugBank indication

Used as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.

Also known as(98)

Brivaracetam

KIAA0736

NAC1

SCN1

Sodium channel protein brain I subunit alpha

Sodium channel protein type I subunit alpha

Voltage-gated sodium channel subunit alpha Nav1.1

hPN3

Dosage forms(31)

Tablet, coated (Oral)

(Intravenous) — 10 mg/ml

Injection, suspension (Intravenous) — 50 mg/5mL

Solution (Intravenous) — 50.000 mg

Solution (Oral) — 1.0000 g

Solution (Oral) — 10 mg/1mL

Tablet (Oral) — 10.000 mg

Tablet, film coated (Oral) — 10 mg/1

Molecular properties(19)

Drug interactions(1661)

Known interactions with other medications. Always consult a healthcare professional.

Buprenorphine

Moderate

DB00921

Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.

Check this interaction

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Brivaracetam.

Check this interaction

Dronabinol

Moderate

DB00470

Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Brivaracetam.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Brivaracetam.

Check this interaction

Hydrocodone

Moderate

DB00956

Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.

Check this interaction

Hydroxyzine

Moderate

DB00557

Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Brivaracetam.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Brivaracetam can be increased when used in combination with Magnesium sulfate.

Check this interaction

Methotrimeprazine

Moderate

DB01403

Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Check this interaction

Metyrosine

Moderate

DB00765

Brivaracetam may increase the sedative activities of Metyrosine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Brivaracetam.

Check this interaction

Mirtazapine

Moderate

DB00370

Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.

Check this interaction

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Brivaracetam.

Check this interaction

Orphenadrine

Moderate

DB01173

Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Check this interaction

Paraldehyde

Moderate

DB09117

Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Check this interaction

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Brivaracetam.

Check this interaction

Pramipexole

Moderate

DB00413

Brivaracetam may increase the sedative activities of Pramipexole.

Check this interaction

Ropinirole

Moderate

DB00268

Brivaracetam may increase the sedative activities of Ropinirole.

Check this interaction

Rotigotine

Moderate

DB05271

Brivaracetam may increase the sedative activities of Rotigotine.

Check this interaction

Rufinamide

Unknown severity

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Brivaracetam.

Check this interaction

Sodium oxybate

Moderate

DB09072

Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.

Check this interaction

Suvorexant

Moderate

DB09034

Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Check this interaction

Tapentadol

Moderate

DB06204

Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Brivaracetam.

Check this interaction

Thalidomide

Moderate

DB01041

Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Check this interaction

Zolpidem

Moderate

DB00425

Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Check this interaction

Mefloquine

Moderate

DB00358

The therapeutic efficacy of Brivaracetam can be decreased when used in combination with Mefloquine.

Check this interaction

Mianserin

Moderate

DB06148

The therapeutic efficacy of Brivaracetam can be decreased when used in combination with Mianserin.

Check this interaction

Orlistat

Moderate

DB01083

Orlistat can cause a decrease in the absorption of Brivaracetam resulting in a reduced serum concentration and potentially a decrease in efficacy.

Check this interaction

Topotecan

Moderate

DB01030

Brivaracetam may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

Methadone

Unknown severity

DB00333

The risk or severity of adverse effects can be increased when Methadone is combined with Brivaracetam.

Check this interaction

Tetracosactide

Unknown severity

DB01284

The risk or severity of liver damage can be increased when Tetracosactide is combined with Brivaracetam.

Check this interaction

Ethanol

Moderate

DB00898

Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Azelastine

Moderate

DB00972

Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Check this interaction

Brimonidine

Moderate

DB00484

Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Brivaracetam.

Check this interaction

Fluvoxamine

Unknown severity

DB00176

The risk or severity of adverse effects can be increased when Brivaracetam is combined with Fluvoxamine.

Check this interaction

Citalopram

Unknown severity

DB00215

The risk or severity of adverse effects can be increased when Brivaracetam is combined with Citalopram.

Check this interaction

Duloxetine

Unknown severity

DB00476

The risk or severity of adverse effects can be increased when Brivaracetam is combined with Duloxetine.

Check this interaction

Trazodone

Unknown severity

DB00656

The risk or severity of adverse effects can be increased when Brivaracetam is combined with Trazodone.

Check this interaction

Paroxetine

Unknown severity

DB00715

The risk or severity of adverse effects can be increased when Brivaracetam is combined with Paroxetine.

Check this interaction

Sibutramine

Unknown severity

DB01105

The risk or severity of adverse effects can be increased when Brivaracetam is combined with Sibutramine.

Check this interaction

Escitalopram

Unknown severity

DB01175

The risk or severity of adverse effects can be increased when Brivaracetam is combined with Escitalopram.

Check this interaction

Zimelidine

Unknown severity

DB04832

The risk or severity of adverse effects can be increased when Brivaracetam is combined with Zimelidine.

Check this interaction

Dapoxetine

Unknown severity

DB04884

The risk or severity of adverse effects can be increased when Brivaracetam is combined with Dapoxetine.

Check this interaction

Milnacipran

Unknown severity

DB04896

The risk or severity of adverse effects can be increased when Brivaracetam is combined with Milnacipran.

Check this interaction

Desvenlafaxine

Unknown severity

DB06700

The risk or severity of adverse effects can be increased when Brivaracetam is combined with Desvenlafaxine.

Check this interaction

Seproxetine

Unknown severity

DB06731

The risk or severity of adverse effects can be increased when Brivaracetam is combined with Seproxetine.

Check this interaction

Levomilnacipran

Moderate

DB08918

Brivaracetam may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.

Check this interaction

Indalpine

Unknown severity

DB08953

The risk or severity of adverse effects can be increased when Brivaracetam is combined with Indalpine.

Check this interaction

Ritanserin

Unknown severity

DB12693

The risk or severity of adverse effects can be increased when Brivaracetam is combined with Ritanserin.

Check this interaction

Alaproclate

Unknown severity

DB13233

The risk or severity of adverse effects can be increased when Brivaracetam is combined with Alaproclate.

Check this interaction

Benzatropine

Moderate

DB00245

Benzatropine may decrease the excretion rate of Brivaracetam which could result in a higher serum level.

Check this interaction

Showing 50 of 1661 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol. Taking Brivaracetam with alcohol may increase alcohol's effects on attention, memory, and psychomotor functioning.

Advice

Take with or without food.

Toxicity & overdose

No carcinogenesis or fertility impairment found. Overdose is associated with somnolence and dizziness [FDA Label].

How it works

Mechanism of action

The precise mechanism of brivaracetam's anti-epileptogenic activity is unknown.

Pharmacodynamics

Brivaracetam binds SV2A with high affinity [A19184]. SV2A is known to play a role in epileptogenesis through modulation of synaptic GABA release [A19185]. It is thought that brivaracetam exerts its anti-epileptogenic effects through its binding to SV2A. Brivaracetam is also known to inhibit Na+ channels which may also contribute to its anti-epileptogenic action [A19186].

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Nearly 100% oral bioavailability .
[A19180]

Half-life

7-8h .
[A19180]

Protein binding

<20% bound to plasma proteins [FDA Label].

Volume of distribution

0.5L/kg [FDA Label].

Metabolism

Primarily metabolized by hydrolysis of the acetamide moeity to form a carboxylic acid metabolite .
[A19188]
Another metabolite is created via oxidation of the propyl side chain by CYP2C8 as well as CYP3A4, CYP2C19, and CYP2B6. Some conjugation with glucuronic acid and taurine account for a small amount of metabolism.

Route of elimination

\>95% excreted in urine with <10% of the parent compound unchanged. <1% excreted in feces [FDA Label].

Clearance

CL/F of 0.7-1.07 mL/min kg .
[A19187]
Clearance is primarily metabolic with less than 10% of the parent drug excreted unchanged.

Drug targets(2)

Proteins and enzymes this drug interacts with in the body

Synaptic vesicle glycoprotein 2A

BE0000993

SV2A

unknown

Specific functionprotein kinase binding

Cellular location

Presynapse

General function & pharmacology

Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles (By similarity)

Sodium channel regulatory subunit beta-4

BE0004901

SCN4B

inhibitor

Specific functionsodium channel regulator activity

Cellular location

Cell membrane

General function & pharmacology

Regulatory subunit of multiple voltage-gated sodium (Nav) channels directly mediating the depolarization of excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient.

The influx of Na+ ions provokes membrane depolarization, initiating the propagation of electrical signals throughout cells and tissues. The accessory beta subunits participate in localization and functional modulation of the Nav channels .
PMID:24297919
Modulates the activity of SCN1A/Nav1.1 .
PMID:33712547
Modulates the activity of SCN2A/Nav1.2 PMID:24297919

Metabolizing enzymes(4)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP3A4Cytochrome P450 3A4

substrate

CYP2C19Cytochrome P450 2C19

substrate

CYP2B6Cytochrome P450 2B6

substrate

CYP2C9Cytochrome P450 2C9

substrate

Scientific references(6)

Rolan P., Sargentini-Maier M.L., Pigeolet E., Stockis A.

The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men.

British Journal of Clinical Pharmacology

2008 Jul66(1):71-5. doi: 10.1111/j.1365-2125.2008.03158.x. Epub 2008 Mar 13

PMID: 18341673 DOI: 10.1111/j.1365-2125.2008.03158.x

Gillard M., Fuks B., Leclercq K., Matagne A.

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.

European Journal Pharmacology

2011 Aug 16664(1-3):36-44. doi: 10.1016/j.ejphar.2011.04.064. Epub 2011 May 8

PMID: 21575627 DOI: 10.1016/j.ejphar.2011.04.064

Tokudome K., Okumura T., Shimizu S., Mashimo T., Takizawa A., Serikawa T., Terada R., Ishihara S., Kunisawa N., Sasa M., Ohno Y.

Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission.

Science Reports

2016 Jun 66:27420. doi: 10.1038/srep27420

PMID: 27265781 DOI: 10.1038/srep27420

Zona C., Pieri M., Carunchio I., Curcio L., Klitgaard H., Margineanu D.G.

Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture.

Epilepsy Research

2010 Jan88(1):46-54. doi: 10.1016/j.eplepsyres.2009.09.024. Epub 2009 Nov 13

PMID: 19914041 DOI: 10.1016/j.eplepsyres.2009.09.024

Sargentini-Maier M.L., Rolan P., Connell J., Tytgat D., Jacobs T., Pigeolet E., Riethuisen J.M., Stockis A.

The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males.

British Journal of Clinical Pharmacology

200763(6):680-688. doi: 10.1111/j.1365-2125.2006.02829.x

PMID: 17223857 DOI: 10.1111/j.1365-2125.2006.02829.x

Sargentini-Maier M.L., Espie P., Coquette A., Stockis A.

Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects.

Drug Metabolism and Disposition

200836(1):36-45. doi: 10.1124/dmd.107.017129

PMID: 17908923 DOI: 10.1124/dmd.107.017129

ATC classification(1 code)

ATC N03AX23

Affected organisms(1)

Humans and other mammals

International brands(1)

Protein Data Bank entries(2)

8k77

8yf1

Commercial products(53)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Brivaracetam

DB05541

CAS number

357336-20-0

UNII (FDA)

U863JGG2IA

InChI Key (molecular fingerprint)

MSYKRHVOOPPJKU-BDAKNGLRSA-N

Additional database identifiers

Drugs Product Database (DPD)

22702

ChEBI

133013

PubChem Compound

9837243

PubChem Substance

347827736

KEGG Drug

D08879

ChemSpider

8012964

BindingDB

50422531

PharmGKB

PA166153491

PDB

VLX

Wikipedia

Brivaracetam

ChEMBL

CHEMBL607400

ZINC

ZINC000003979899

RxCUI

1739745

HUGO Gene Nomenclature Committee (HGNC)

HGNC:20566

GenAtlas

SV2A

GeneCards

SV2A

GenBank Gene Database

AB018279

GenBank Protein Database

40788343

UniProtKB

Q7L0J3

UniProt Accession

SV2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10585

GenAtlas

SCN1A

GeneCards

SCN1A

GenBank Gene Database

AF225985

GenBank Protein Database

12642270

IUPHAR

578

Guide to Pharmacology

578

UniProtKB

P35498

UniProt Accession

SCN1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10582

GenAtlas

SCN10A

GeneCards

SCN10A

GenBank Gene Database

AF117907

GenBank Protein Database

4838145

IUPHAR

585

Guide to Pharmacology

585

UniProtKB

Q9Y5Y9

UniProt Accession

SCNAA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10583

GenAtlas

SCN11A

GeneCards

SCN11A

GenBank Gene Database

AF188679

GenBank Protein Database

6572950

IUPHAR

586

UniProtKB

Q9UI33

UniProt Accession

SCNBA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10588

GenAtlas

SCN2A

GeneCards

SCN2A

GenBank Gene Database

M94055

GenBank Protein Database

457879

IUPHAR

579

Guide to Pharmacology

579

UniProtKB

Q99250

UniProt Accession

SCN2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10590

GenAtlas

SCN3A

GeneCards

SCN3A

GenBank Gene Database

AJ251507

GenBank Protein Database

7414320

IUPHAR

580

Guide to Pharmacology

580

UniProtKB

Q9NY46

UniProt Accession

SCN3A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10591

GenAtlas

SCN4A

GeneCards

SCN4A

GenBank Gene Database

M81758

GenBank Protein Database

338213

IUPHAR

581

Guide to Pharmacology

581

UniProtKB

P35499

UniProt Accession

SCN4A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10593

GenAtlas

SCN5A

GeneCards

SCN5A

GenBank Gene Database

M77235

GenBank Protein Database

184039

IUPHAR

582

Guide to Pharmacology

582

UniProtKB

Q14524

UniProt Accession

SCN5A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10594

GeneCards

SCN7A

UniProtKB

Q01118

UniProt Accession

SCN7A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10596

GenAtlas

SCN8A

GeneCards

SCN8A

GenBank Gene Database

AF050736

GenBank Protein Database

4321647

IUPHAR

583

Guide to Pharmacology

583

UniProtKB

Q9UQD0

UniProt Accession

SCN8A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10597

GenAtlas

SCN9A

GeneCards

SCN9A

GenBank Gene Database

X82835

GenBank Protein Database

758110

IUPHAR

584

Guide to Pharmacology

584

UniProtKB

Q15858

UniProt Accession

SCN9A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10586

GeneCards

SCN1B

GenBank Gene Database

L10338

GenBank Protein Database

307415

UniProtKB

Q07699

UniProt Accession

SCN1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10589

GeneCards

SCN2B

GenBank Gene Database

AF007783

GenBank Protein Database

3309111

UniProtKB

O60939

UniProt Accession

SCN2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:20665

GeneCards

SCN3B

GenBank Gene Database

AJ243396

GenBank Protein Database

7160975

UniProtKB

Q9NY72

UniProt Accession

SCN3B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10592

GeneCards

SCN4B

GenBank Gene Database

AY149967

GenBank Protein Database

27465047

UniProtKB

Q8IWT1

UniProt Accession

SCN4B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2615

GeneCards

CYP2B6

GenBank Gene Database

M29874

GenBank Protein Database

181296

Guide to Pharmacology

1324

UniProtKB

P20813

UniProt Accession

CP2B6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

Patent information

1 active patent, 3 expired

10729653

United States

Approved 4 Aug 2020 · Expires 9 Apr 2030

4 years

6911461

United States

Approved 28 Jun 2005 · Expires 21 Feb 2021

Expired

6784197

United States

Approved 31 Aug 2004 · Expires 21 Feb 2021

Expired

8492416

United States

Approved 23 Jul 2013 · Expires 21 Feb 2021

Expired

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 26 days ago(8 Mar 2026)

Back to medicines

Brivaracetam 75mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

NICE clinical guidance(2)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
6

Chemical identifiers

Brivaracetam

Additional database identifiers

Patent information

DrugBank citations

Brivaracetam 75mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(2)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science6

Chemical identifiers

Brivaracetam

Additional database identifiers

Patent information

DrugBank citations

Deep science
6